Thomas Schinecker, Roche Chief Executive Officer, discusses the company's performance as third-quarter sales rose 9% to 15.1 billion Swiss francs ($17.5 billion). "We're very confident that we can carry this momentum towards the end of the year but also into the next year," he said. Speaking on Bloomberg Television, Schinecker also discusses Roche's portfolio plans and the clinical trials for Parkinson's and Alzheimer's disease drugs.